Vividion Therapeutics

Building the Future for Vividion Therapeutics

Vividion Therapeutics, a wholly-owned subsidiary of Bayer AG, has embarked on an ambitious project to transform 127,382 RSF into a cutting-edge facility designed for breakthrough innovation. With McFarlane Architects leading the design and DPR Construction at the helm, the project combines state-of-the-art biology, tissue culture, chemistry, mass spectrometry, and vivarium spaces with offices, meeting areas, and ancillary uses.

Scheduled for completion in late 2025, this Tenant Improvement transformation integrates low-voltage systems, telecommunications, critical utility upgrades, and security infrastructure. Thoughtful interior finishing and design, paired with a meticulous assessment of existing conditions, ensure every element is optimized for functionality and aesthetics. The MEP design-build process, alongside FF&E and laboratory fit-outs, underscores the project’s focus on excellence and precision.

At Intersect Management, we take pride in being trusted partners in projects like this—delivering expertise and a collaborative approach to help turn vision into reality. Let’s build your future, together.